Addex to Receive CHF850,000 ($900,000) of Additional Funding; Addex’s Reserved Indications Expanded to include Chronic Cough
Ad Hoc Announcement Pursuant to Art. 53 LR
Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that its collaboration agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates has been extended until March 31, 2023. As part of the amended agreement, Indivior will provide Addex with CHF 850,000 (approx. US $900,000) of additional research funding. The reserved indications, where Addex retains exclusive rights to develop its own independent GABAB PAM program, have also been expanded to include chronic cough, in addition to the rights to develop certain retained compounds for Charcot-Marie-Tooth type 1A neuropathy (CMT1A) and pain.
“We have advanced the GABAB PAM program into the late stage of clinical candidate selection and are currently selecting compounds for entry into IND enabling studies for both Indivior’s program in substance use disorder and Addex’s independent programs for CMT1A, chronic cough and pain,” said Mikhail Kalinichev, Head of Translational Science of Addex. “This additional research funding demonstrates the progress made to date in identifying novel GABAB PAM drug candidates and reflects the promise this mechanism of action has to bring significant benefit to the quality of life of patients”.
“Indivior continues to be an important strategic partner for Addex as we continue to advance our preclinical portfolio towards the clinic and await the readout from the ADX71149 Phase 2 epilepsy study being conducted by our partner, Janssen Pharmaceuticals Inc., which is due to report top line data at the end of 2022,” said Tim Dyer, CEO of Addex. “We also continue to advance discussions with potential partners across our portfolio and evaluate the future development path for dipraglurant, our mGlu5 NAM clinical program.”
About GABAB Activation with PAM
Activation of gamma-aminobutyric acid subtype B (GABAB) receptor, a Family C class of GPCR, is clinically and commercially validated. The generic GABAB receptor agonist, baclofen, marketed for spasticity and some spinal cord injuries, has been shown to be efficacious in several other disease areas, including alcohol use disorder, CMT1A, chronic cough and pain. However, its wider use is limited due to a variety of side effects, rapid clearance and the development of tolerance. Novel, potent, selective and orally available positive allosteric modulators (PAMs) that potentiate GABA responses, rather than acting as orthosteric agonists at the GABAB receptor, like baclofen, are expected to deliver efficacy and have less adverse effects. Furthermore, PAMs only act when the natural ligand (GABA) activates the receptor, hence respecting the physiological cycle of activation, which is believed to explain why PAMs lead to less tolerance than direct agonists.
About Addex Therapeutics: Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available, small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional, non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is in a Phase 2a proof of concept clinical trial for the treatment of epilepsy. Addex's second clinical program, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in a range of indications. Indivior PLC has licensed Addex’s GABAB PAM program for the development of drug candidates, with a focus on substance use disorder. Addex is also advancing a broad preclinical pipeline, which includes development of a range of GABAB PAMs for CMT1A, chronic cough and several types of pain, mGlu7 NAM for stress related disorders, mGlu2 NAM for mild neurocognitive disorders and depression, M4 PAM for schizophrenia and other forms of psychosis, as well as mGlu4 PAM and mGlu3 PAM. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol "ADXN" on each exchange.
Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com
Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including the ability to discover molecules as part of the Indivior collaboration mentioned above, the progress of clinical trials and preclinical studies, including the timing of data read-outs from the ADX71149 epilepsy study, and our intended strategic direction. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, such as receipt of ongoing research payments and timing of the collaboration conclusion, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2021, as filed with the SEC on March 10, 2022, the prospectus supplement and accompanying prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
A provincial capital in southwest China has dimmed outdoor advertisements, subway lighting and building signs to save energy, official announcements said, as the area battles a power crunch triggered by record-high temperatures.
At least 10 crypto firms have gone bust or have suspended withdrawals since the beginning of the year
The price of dogecoin jumped this week after the new Dogechain platform gained traction from retail investors.
Re-branded as Stars Coffee, the successor of Starbucks welcomed its first visitors in Moscow on Friday after the Seattle-based coffee shop chain withdrew from the Russian market over the conflict in Ukraine.
European and US stocks mostly fell Friday, with investors focused firmly on central bank interest rate hikes as the US dollar rallied.
Waxing is a method of removing unwanted hair from the roots, using hair removal wax. When applied to the skin, wax is a sticky substance that sticks to body hair. The hair from the follicle is removed by pulling on its covering.New York, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hair Removal Wax Market Size, Share & Industry Trends Analysis Report By Gender, By Type, By Distribution Channel, By Regional Outlook and Forecast, 2022 - 2028" - htt
Analysts had forecast £2.8bn for the month.
A rocker switch is a type of switch that, when pressed, moves back and forth by raising one end and depressing the other, much like a seesaw, as opposed to tripping or remaining depressed.New York, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rocker Switch Market Size, Share & Industry Trends Analysis Report By Switching Configuration, By Vertical, By Regional Outlook and Forecast, 2022 - 2028" - https://www.reportlinker.com/p06315052/?utm_source
LONDON (Reuters) -The company which operates Britain's biggest container port, Felixstowe, said on Friday it believed its pay offer to workers was fair and it was disappointed strike action due to begin on Sunday had not been called off. More than 1,900 workers at Felixstowe represented by the Unite union plan eight days of strikes from Aug. 21 in a dispute over pay. "The company is disappointed that Unite has not taken up our offer to call off the strike and come to the table for constructive discussions to find a resolution," said a spokesperson for Hutchison Ports, which operates Felixstowe.
(Reuters) -European shares fell on Friday and posted a weekly loss as the highest-ever jump in German producer prices in July added to gloom over the economic outlook for the region's biggest economy and rekindled fears of a recession. Rising energy prices due to the Ukraine war pushed German producer costs in July to their highest ever increases both year-on-year and month-on-month. "European markets appear to have run out of puff this week, spooked in some part perhaps by the big jumps in inflation we've seen in UK CPI this week, as well as this morning's eye-watering surge in German PPI for July," said Michael Hewson, chief market analyst at CMC Markets UK.
Sophie Flynn had a decade-long professional football career before becoming co-founder of global payments platform Transact365.
Many middle- and lower-income Americans are left with a dwindling number of options or forced into renting while supply increases for the wealthiest buyers
Product Overview Replacement for breast milk is infant feeding. The initial six months after birth play a crucial role in the development of an infant, which is of vital importance in ensuring adequate nutrition during this time.New York, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Infant Formula Market: Market Segments: By Ingredient Type ; By Application; By Distribution Channel ; and Region – Analysis of Market Size, Share & Trends for 2014 –
The ads could fail to warn people of the risks of taking on debt they cannot afford to repay, the FCA said.
The Evening Standard New Homes Awards celebrate the ambitious projects and new neighbourhoods being created in the capital and beyond.
DP World saw its profit soar by more than 50% in the first six months of the year.
Product Overview Replacement for breast milk is infant feeding. The initial six months after birth play a crucial role in the development of an infant, which is of vital importance in ensuring adequate nutrition during this time.New York, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Infant Formula Market: Market Segments: By Ingredient Type ; By Application; By Distribution Channel ; and Region – Analysis of Market Size, Share & Trends for 2014 –
Global Prebiotics Market Global Prebiotics Market Dublin, Aug. 19, 2022 (GLOBE NEWSWIRE) -- The "Global Prebiotics Market Size, Share & Trends Analysis Report by Ingredients (FOS, Inulin, GOS, MOS), by Application (Food & Beverages, Dietary Supplements, Animal Feed), by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global prebiotics market size is expected to reach USD 21.2 billion by 2030, registering a CAGR of 14.9% The growing demand
Shares dived by two-thirds within minutes of reports by the Wall Street Journal
Security experts say that users should update all affected Apple devices